Interestingly, anti-TNF-α therapy has been shown to improve markers of bone metabolism and BMD (i.e., osteocalcin, alkaline phosphatase, and P1NP) by decreasing serum OPG levels in IBD patients [117–120]. The gene discussed is TNFRSF11B; the disease is inflammatory bowel disease.